Daiichi Sankyo (OTCMKTS:DSNKY) Trading Down 6.3% – Should You Sell?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price was down 6.3% during mid-day trading on Wednesday . The company traded as low as $17.80 and last traded at $17.85. Approximately 24,255 shares traded hands during trading, a decline of 95% from the average daily volume of 463,447 shares. The stock had previously closed at $19.05.

Daiichi Sankyo Stock Down 1.7%

The business’s 50 day simple moving average is $18.45 and its 200-day simple moving average is $21.17. The company has a market cap of $33.73 billion, a price-to-earnings ratio of 16.33, a price-to-earnings-growth ratio of 0.98 and a beta of -0.04. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69.

Daiichi Sankyo (OTCMKTS:DSNKY) last issued its earnings results on Thursday, January 29th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.05. The company had revenue of $3.65 billion during the quarter, compared to analyst estimates of $3.88 billion. Daiichi Sankyo had a net margin of 14.83% and a return on equity of 18.64%. Sell-side analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 1.04 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.